Helen P Hazuda1, Sarah A Gaussoin2, Rena R Wing3, Susan Z Yanovski4, Karen C Johnson5, Mace Coday5, Thomas A Wadden6, Edward S Horton7, Brent Van Dorsten8, William C Knowler4. 1. The University of Texas Health Science Center at San Antonio, San Antonio, TX hazuda@uthscsa.edu. 2. Wake Forest School of Medicine, Winston-Salem, NC. 3. The Miriam Hospital/Brown Medical School, Providence, RI. 4. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 5. The University of Tennessee, Memphis, TN. 6. University of Pennsylvania, Philadelphia, PA. 7. Joslin Diabetes Center, Boston, MA. 8. Colorado Center for Behavioral Medicine, Denver, CO.
Abstract
OBJECTIVE: To examine whether depression symptoms or antidepressant medication (ADM) use predicts the probability of cardiovascular events in overweight/obese individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS: Preplanned analyses of depression and incident cardiovascular disease (CVD) were performed in the Look AHEAD (Action for Health in Diabetes) weight loss trial after a median follow-up of 9.6 years. Depression symptoms, assessed with the Beck Depression Inventory (BDI), were analyzed both as a continuous and dichotomized variable (BDI score <10 or ≥10). ADM use was coded from participants' prescription medications. Four composite CVD outcomes were defined in the study protocol. Sex-stratified Cox proportional hazards models were adjusted for a range of baseline covariates. RESULTS: Depression symptoms were only significantly associated with a composite secondary outcome comprising CVD death, nonfatal myocardial infarction, nonfatal stroke, hospitalized angina, congestive heart failure, peripheral vascular disease, coronary artery bypass graft, and carotid endarterectomy. Significant sex interactions were observed for BDI score and BDI score ≥10. BDI score was significantly associated with higher probability of this composite outcome in men but was not associated with the outcome in women. BDI score ≥10 was positively associated with this composite outcome in men but was negatively associated in women. Exploratory analysis identified a significant BDI ≥10 × ADM use interaction for this composite outcome that differed in men versus women. Men with both BDI score ≥10 and ADM use compared with those with neither had 60% higher probability of the outcome, whereas women with both compared with those with neither had 50% lower probability. CONCLUSIONS: Sex differences in the association of depression symptoms and ADM use with incident CVD warrant further investigation.
OBJECTIVE: To examine whether depression symptoms or antidepressant medication (ADM) use predicts the probability of cardiovascular events in overweight/obese individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS: Preplanned analyses of depression and incident cardiovascular disease (CVD) were performed in the Look AHEAD (Action for Health in Diabetes) weight loss trial after a median follow-up of 9.6 years. Depression symptoms, assessed with the Beck Depression Inventory (BDI), were analyzed both as a continuous and dichotomized variable (BDI score <10 or ≥10). ADM use was coded from participants' prescription medications. Four composite CVD outcomes were defined in the study protocol. Sex-stratified Cox proportional hazards models were adjusted for a range of baseline covariates. RESULTS:Depression symptoms were only significantly associated with a composite secondary outcome comprising CVD death, nonfatal myocardial infarction, nonfatal stroke, hospitalized angina, congestive heart failure, peripheral vascular disease, coronary artery bypass graft, and carotid endarterectomy. Significant sex interactions were observed for BDI score and BDI score ≥10. BDI score was significantly associated with higher probability of this composite outcome in men but was not associated with the outcome in women. BDI score ≥10 was positively associated with this composite outcome in men but was negatively associated in women. Exploratory analysis identified a significant BDI ≥10 × ADM use interaction for this composite outcome that differed in men versus women. Men with both BDI score ≥10 and ADM use compared with those with neither had 60% higher probability of the outcome, whereas women with both compared with those with neither had 50% lower probability. CONCLUSIONS: Sex differences in the association of depression symptoms and ADM use with incident CVD warrant further investigation.
Authors: C Barr Taylor; Marston E Youngblood; Diane Catellier; Richard C Veith; Robert M Carney; Matthew M Burg; Peter G Kaufmann; John Shuster; Thomas Mellman; James A Blumenthal; Ranga Krishnan; Allan S Jaffe Journal: Arch Gen Psychiatry Date: 2005-07
Authors: B W Penninx; J M Guralnik; C F Mendes de Leon; M Pahor; M Visser; M C Corti; R B Wallace Journal: Am J Cardiol Date: 1998-04-15 Impact factor: 2.778
Authors: Emelia J Benjamin; Salim S Virani; Clifton W Callaway; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Stephanie E Chiuve; Mary Cushman; Francesca N Delling; Rajat Deo; Sarah D de Ferranti; Jane F Ferguson; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Pamela L Lutsey; Jason S Mackey; David B Matchar; Kunihiro Matsushita; Michael E Mussolino; Khurram Nasir; Martin O'Flaherty; Latha P Palaniappan; Ambarish Pandey; Dilip K Pandey; Mathew J Reeves; Matthew D Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Uchechukwu K A Sampson; Gary M Satou; Svati H Shah; Nicole L Spartano; David L Tirschwell; Connie W Tsao; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2018-01-31 Impact factor: 29.690
Authors: Rena R Wing; Paula Bolin; Frederick L Brancati; George A Bray; Jeanne M Clark; Mace Coday; Richard S Crow; Jeffrey M Curtis; Caitlin M Egan; Mark A Espeland; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Barbara Harrison; Helen P Hazuda; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Maria G Montez; Anne Murillo; David M Nathan; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Judith G Regensteiner; Amy D Rickman; Donna H Ryan; Monika Safford; Thomas A Wadden; Lynne E Wagenknecht; Delia S West; David F Williamson; Susan Z Yanovski Journal: N Engl J Med Date: 2013-06-24 Impact factor: 91.245
Authors: Xiaobo Liu; Yuxi Li; Li Guan; Xia He; Huiling Zhang; Jun Zhang; Juan Li; Dongling Zhong; Rongjiang Jin Journal: Front Med (Lausanne) Date: 2022-05-10
Authors: Inmaculada Guerrero Fernández de Alba; Antonio Gimeno-Miguel; Beatriz Poblador-Plou; Luis Andrés Gimeno-Feliu; Ignatios Ioakeim-Skoufa; Gemma Rojo-Martínez; Maria João Forjaz; Alexandra Prados-Torres Journal: Sci Rep Date: 2020-11-11 Impact factor: 4.379
Authors: Xiaobo Liu; Chao Dong; Hong Jiang; Dongling Zhong; Yuxi Li; Huiling Zhang; Jun Zhang; Jin Fan; Juan Li; Li Guan; Rongjiang Jin Journal: Syst Rev Date: 2021-11-25
Authors: Thomas A Wadden; Ariana M Chao; Harelda Anderson; Kirsten Annis; Karen Atkinson; Paula Bolin; Phillip Brantley; Jeanne M Clark; Mace Coday; Gareth Dutton; John P Foreyt; Edward W Gregg; Helen P Hazuda; James O Hill; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; William C Knowler; Mary Korytkowski; Cora E Lewis; Blandine Laferrère; Roeland J Middelbeek; Medha N Munshi; David M Nathan; Rebecca H Neiberg; Scott J Pilla; Anne Peters; Xavier Pi-Sunyer; Jack W Rejeski; Bruce Redmon; Tiffany Stewart; Elizabeth Vaughan; Lynne E Wagenknecht; Michael P Walkup; Rena R Wing; Holly Wyatt; Susan Z Yanovski; Ping Zhang Journal: Obesity (Silver Spring) Date: 2021-07-14 Impact factor: 9.298
Authors: Yulia Khodneva; Parag Goyal; Emily B Levitan; Elizabeth A Jackson; Suzanne Oparil; Madeline R Sterling; Andrea L Cherrington; Raegan Durant; Monika M Safford Journal: J Am Heart Assoc Date: 2022-03-24 Impact factor: 6.106